Nimble Therapeutics Expands its Drug Discovery Capabilities to Advance Pipeline to the Clinic
Retrieved on:
Wednesday, April 3, 2024
Oncology, Health, Infectious Diseases, Radiology, Pharmaceutical, Biotechnology, Pfizer, De Montfort University, Drug discovery, Yale University, BU, Harvard University, Patient, Flavell, Immunology, Merck, Head, Wetzler, Merck & Co., IND, Rhône-Poulenc, Therapy, CSO, American Chemical Society, Medicinal chemistry, Peptide, Pharmaceutical industry
In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
Key Points:
- In addition to the new site, Nimble also announced the appointment of two senior leaders to spearhead the drug discovery efforts and catalyze the build out of the Philadelphia site and team.
- Shelley Allen will join as Head of Drug Discovery and will lead the advanced optimization and characterization of clinical candidate peptides and their progression into the clinic.
- Munir Mosaheb will join as Head of Biology and will lead the pharmacological, immunological and translational aspects of Nimble’s drug discovery programs.
- She joined Nimble from Think Bioscience where she was VP, Medicinal Chemistry, and responsible for establishing drug discovery teams and capabilities to develop their internal programs.